MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
Open accessAbstract
A new class of chemotherapeutic agents, MEK inhibitors, has recently been developed and is proving to be an effective treatment for a number of cancers. A pattern of ocular adverse events has followed these drugs through clinical trials and their association with retinopathy is only just beginning to be recognized. We present two cases of MEK inhibitor-associated retinopathy followed by a review of the current literature on ocular toxicity associated with MEK inhibitors. Patients undergoing treatment with MEK inhibitors appear to have high rates of multifocal serous retinal detachments as well as retinal vein occlusions. We present the first report of cystoid macular edema associated with MEK inhibitor use. The mechanism of these adverse events is still unclear though they seem to be related to oxidative stress and blood retinal barrier breakdown. Management of the ocular toxicity can range from observation to topical treatments or intravitreal injections. Fortunately most ocular adverse events appear to be self-limited and do not require discontinuing the MEK inhibitor. Discontinuation or decreased dosing of MEK inhibitors may be reserved for cases of severe sight-threatening ocular toxicity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibitors of the ERK1/2 pathway used in cancer therapy may provoke ocular secondary effects.
“Inhibitors of the ERK1/2 pathway used in cancer therapy may provoke ocular secondary effects”
From Loss of Extracellular Signal-Regulated Kinase 1/2 in the Retinal Pigment Epithelium Leads to RPE65 Decrease and Retinal Degeneration (2017) · cites this paper as [21]
Several MEK1/2 inhibitors have been clinically evaluated for cancer therapy, but some early-phase trials were stopped prematurely because of toxicity issues, including various ocular adverse effects.
“Several MEK1/2 inhibitors have been clinically evaluated for cancer therapy, but some of these early-phase trials were stopped prematurely because of toxicity issues, including various ocular adverse effects ( 21 , 68 – 70 ).”
From Loss of Extracellular Signal-Regulated Kinase 1/2 in the Retinal Pigment Epithelium Leads to RPE65 Decrease and Retinal Degeneration (2017) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,149 · see citing works
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330 · see citing works
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 918 · see citing works
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645 · see citing works
Adjei, A. A., Cohen, R. B., Franklin, W. A., Morris, C. D., Wilson, D. M., Molina, J. R., Hanson, L. J., Gore, L., Chow, L. Q. M., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 568 · see citing works
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552 · see citing works
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P. G., Moy, C. H., Szabo, S. A., Roadcap, L., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70269-3 · Cited by 547 · see citing works
Kim, K. B., Kefford, R. F., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 475 · see citing works
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 403 · see citing works
LoRusso, P. M., Adjei, A. A., Varterasian, M. L., Gadgeel, S. M., Reid, J. M., Mitchell, D. Y., Hanson, L. J., DeLuca, P., Bruzek, L. M., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 402 · see citing works
MEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291 · see citing works
LoRusso, P. M., Krishnamurthi, S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 253 · see citing works
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 212 · see citing works
Clinical experience of MEK inhibitors in cancer therapy
Wang, D., Boerner, S. A., Winkler, J. D., & LoRusso, P. M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.009 · Cited by 173 · see citing works
Martinez‐García, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S. O., Kraeber‐Bodéré, F., Rojo, F., Routier, É., Guarin, E., Xu, Z., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0742 · Cited by 153 · see citing works
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139 · see citing works
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 134 · see citing works
Targeting MAPK pathway in melanoma therapy
Cheng, Y., Zhang, G., & Li, G. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9433-9 · Cited by 97 · see citing works
Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L. D., Ko, M., Aguirre, S. A., & Younis, H. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0060 · Cited by 90 · see citing works
McCannel, T. A., Chmielowski, B., Finn, R. S., Goldman, J., Ribas, A., Wainberg, Z. A., & McCannel, C. A. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.976 · Cited by 90 · see citing works
Jiang (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000191 · Cited by 81 · see citing works
Schoenberger, S. D., & Kim, S. J. (2013) · Case Reports in Ophthalmological Medicine · doi:10.1155/2013/673796 · Cited by 46 · see citing works
Shibata, M., Oku, H., Sugiyama, T., Kobayashi, T., Tsujimoto, M., Okuno, T., & Ikeda, T. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6605 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · see citing works
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Francis, J. H., Habib, L. A., Abramson, D. H., Yannuzzi, L. A., Heinemann, M., Gounder, M. M., Grisham, R. N., Postow, M. A., Shoushtari, A. N., Chi, P., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.038 · Cited by 141 · see citing works
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117 · see citing works
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R., & Goldinger, S. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.018 · Cited by 82 · see citing works
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30464-2 · Cited by 78 · see citing works
Ocular Safety Profile of BRAF and MEK Inhibitors
Mettler, C., Monnet, D., Kramkimel, N., Tréluyer, J.-M., Mouthon, L., Brézin, A., Dupin, N., Valnet-Rabier, M.-B., Chouchana, L., & Terrier, B. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.05.008 · Cited by 40 · see citing works
New features in MEK retinopathy
Tyagi, P., & Santiago, C. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0861-8 · Cited by 39 · see citing works
Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., et al. (2019) · Retina · doi:10.1097/iae.0000000000002027 · Cited by 31 · see citing works
Pyakurel, A., Balmer, D., Saba-El-Leil, M. K., Kizilyaprak, C., Daraspe, J., Humbel, B. M., Voisin, L., Le, Y. Z., von Lintig, J., Meloche, S., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00295-17 · Cited by 20 · see citing works
“by mechanism-based side effects of blurred vision and altered light perception (20, 21).”
BackgroundMita, M., Fu, S., Piha-Paul, S. A., Janku, F., Mita, A., Natale, R., Guo, W., Zhao, C., Kurzrock, R., & Naing, A. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0442-3 · Cited by 26 · see citing works
Francis, J. H., Canestraro, J., Haggag-Lindgren, D., Harding, J. J., Diamond, E. L., Drilon, A., Li, B. T., Iyer, G., Schram, A. M., & Abramson, D. H. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.06.001 · Cited by 15 · see citing works
Pimasertib-associated ophthalmological adverse events
van Dijk, E. H. C., Kruit, W. H. J., Jager, M. J., Luyten, G. P. M., Vingerling, J. R., & Boon, C. J. F. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13677 · Cited by 9 · see citing works
- Authors
- Duncan, K. E., Chang, L. Y., & Patronas, M.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Duncan, K E
- Venue
- Eye
- Published
- 2015-06-05
- Volume
- 29
- Issue
- 8
- Pages
- 1003-1012
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC4541356
- OpenAlex
- W584714177
- Cited by
- 87
- References
- 24
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 5 · 2020: 11 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 8 · 2015: 2
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Eye (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Keywords
- MEK inhibitors, ocular toxicity, retinopathy, serous retinal detachment, retinal vein occlusion, cystoid macular edema, blood-retinal barrier breakdown, oxidative stress, adverse drug reactions, intravitreal injection, topical treatment, cancer chemotherapy
- MeSH terms
- Antineoplastic Agents, Female, Humans, Macular Edema, Male, Middle Aged, Retinal Diseases, Mitogen-Activated Protein Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
